Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Mature osteoclasts degrade bone matrix by exocytosis of active proteases from secretory lysosomes through a ruffled border. However, the molecular mechanisms underlying lysosomal trafficking and secretion in osteoclasts remain largely unknown. Here, we show with GeneChip analysis that RUN and FYVE domain-containing protein 4 (RUFY4) is strongly upregulated during osteoclastogenesis. Mice lacking Rufy4 exhibited a high trabecular bone mass phenotype with abnormalities in osteoclast function in vivo. Furthermore, deleting Rufy4 did not affect osteoclast differentiation, but inhibited bone-resorbing activity due to disruption in the acidic maturation of secondary lysosomes, their trafficking to the membrane, and their secretion of cathepsin K into the extracellular space. Mechanistically, RUFY4 promotes late endosome-lysosome fusion by acting as an adaptor protein between Rab7 on late endosomes and LAMP2 on primary lysosomes. Consequently, Rufy4-deficient mice were highly protected from lipopolysaccharide- and ovariectomy-induced bone loss. Thus, RUFY4 plays as a new regulator in osteoclast activity by mediating endo-lysosomal trafficking and have a potential to be specific target for therapies against bone-loss diseases such as osteoporosis.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11094054PMC
http://dx.doi.org/10.1038/s41413-024-00326-8DOI Listing

Publication Analysis

Top Keywords

bone loss
8
endo-lysosomal trafficking
8
rufy4
6
rufy4 deletion
4
deletion prevents
4
prevents pathological
4
bone
4
pathological bone
4
loss blocking
4
blocking endo-lysosomal
4

Similar Publications

Importance: Neonatal intensive care has advanced over recent decades, yet premature birth remains associated with increased neonatal mortality and morbidity.

Objective: To describe health service use, morbidity, and medication needs up to age 5 years in a contemporary cohort of children born preterm.

Design, Setting, And Participants: This population-based cohort study was conducted in British Columbia (BC), Canada, using health service and pharmacy data linked using provincial administrative databases.

View Article and Find Full Text PDF

Effects of Glucagon-Like Peptide-1 receptor agonists on bone health in people living with obesity.

Osteoporos Int

September 2025

Department of Rheumatology, Univ. Lille, CHU Lille, MABlab ULR 4490, 59000, Lille, France.

Medications like liraglutide 3.0 mg daily (Saxenda®; Novo Nordisk) and semaglutide 2.4 mg weekly (Wegovy®; Novo Nordisk), which are glucagon-like peptide-1 receptor agonists (GLP-1Ra), have been sanctioned for prolonged weight management in people living with obesity (PwO).

View Article and Find Full Text PDF

Unlabelled: The study explored osteoporosis patients' views on the disease in six LATAM countries. All were diagnosed for over 3 years, 65% avoiding fragility fractures. Sixteen used osteoporosis drugs, trusting physicians most.

View Article and Find Full Text PDF

Purpose: To evaluate changes in implant stability quotient values of hydrophilic tissue-level implants over time, and to investigate the influence of local factors on variations in these values.

Methods: Fifty tapered, self-tapping, tissue-level implants with a hydrophilic surface were placed and monitored for 12 months. Implant stability quotient values were recorded at the time of insertion (T0) and monthly thereafter for 12 months.

View Article and Find Full Text PDF

Background: Certain 3D interrelationships between adjacent implants can potentially predispose to prosthetic and biological complications.

Materials And Methods: Patient records with adjacent dental implants were assessed to evaluate the effects of vertical, horizontal and angulation interrelationships between splinted compared to non-splinted implant restorations on the occurrence of biological and prosthetic complications. Data on patient- and implant-related variables were collected at baseline (T1) during prosthesis placement and at the last follow-up appointment (T2).

View Article and Find Full Text PDF